Literature DB >> 11543872

Cocaine affects the dynamics of cytoskeletal proteins via sigma(1) receptors.

T P Su1, T Hayashi.   

Abstract

Cytoskeletal proteins are important in protein trafficking, membrane protein clustering, dendrite growth and the morphological maintenance of neurons. Sigma(1) receptors are unique endoplasmic reticular (ER) proteins that bind (+)benzomorphans, neurosteroids and psychotropic drugs such as cocaine. Cocaine, via sigma(1) receptors, can cause the dissociation of a cytoskeletal adaptor protein ankyrin from inositol (1,4,5)-trisphosphate [Ins(1,4,5)P(3)] receptors on the ER as a sigma(1)-receptor-ankyrin complex, which then translocates to the plasma membrane and nucleus. The dissociation of sigma(1)-receptor-ankyrin from Ins(1,4,5)P(3) receptors also increases the intracellular Ca(2+) concentration [[Ca(2+)](i)], which affects the activity of cytoskeletal proteins. Furthermore, cocaine might increase [Ca(2+)](i) via phospholipase C (PLC)-linked dopamine D1 receptors. We hypothesize that cocaine might cause life-long changes in neurons via cytoskeletal proteins by interacting with both D1 receptors and sigma(1) receptors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11543872     DOI: 10.1016/s0165-6147(00)01740-5

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  17 in total

Review 1.  Sigma receptors: biology and therapeutic potential.

Authors:  Xavier Guitart; Xavier Codony; Xavier Monroy
Journal:  Psychopharmacology (Berl)       Date:  2004-06-10       Impact factor: 4.530

2.  Sigma1 receptor upregulation after chronic methamphetamine self-administration in rats: a study with yoked controls.

Authors:  Roman Stefanski; Zuzana Justinova; Teruo Hayashi; Minoru Takebayashi; Steven R Goldberg; Tsung-Ping Su
Journal:  Psychopharmacology (Berl)       Date:  2004-03-17       Impact factor: 4.530

3.  The sigma receptor: evolution of the concept in neuropsychopharmacology.

Authors:  T Hayashi; Tp Su
Journal:  Curr Neuropharmacol       Date:  2005-10       Impact factor: 7.363

Review 4.  Systems-level view of cocaine addiction: the interconnection of the immune and nervous systems.

Authors:  Christina C Marasco; Cody R Goodwin; Danny G Winder; Nicole L Schramm-Sapyta; John A McLean; John P Wikswo
Journal:  Exp Biol Med (Maywood)       Date:  2014-06-05

5.  Mechanisms of activation of nucleus accumbens neurons by cocaine via sigma-1 receptor-inositol 1,4,5-trisphosphate-transient receptor potential canonical channel pathways.

Authors:  Jeffrey L Barr; Elena Deliu; G Cristina Brailoiu; Pingwei Zhao; Guang Yan; Mary E Abood; Ellen M Unterwald; Eugen Brailoiu
Journal:  Cell Calcium       Date:  2015-05-27       Impact factor: 6.817

6.  Decreases in cocaine self-administration with dual inhibition of the dopamine transporter and σ receptors.

Authors:  Takato Hiranita; Paul L Soto; Stephen J Kohut; Theresa Kopajtic; Jianjing Cao; Amy H Newman; Gianluigi Tanda; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2011-08-22       Impact factor: 4.030

Review 7.  Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders.

Authors:  Teruo Hayashi; Tsung-Ping Su
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

8.  Potentiation of N-methyl-D-aspartate receptor-mediated neuronal injury during methamphetamine withdrawal in vitro requires co-activation of IP3 receptors.

Authors:  Katherine J Smith; Tracy R Butler; Rachel L Self; Brittany B Braden; Mark A Prendergast
Journal:  Brain Res       Date:  2007-10-18       Impact factor: 3.252

9.  Reinforcing effects of sigma-receptor agonists in rats trained to self-administer cocaine.

Authors:  Takato Hiranita; Paul L Soto; Gianluigi Tanda; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2009-11-05       Impact factor: 4.030

10.  Pharmacology and therapeutic potential of sigma(1) receptor ligands.

Authors:  E J Cobos; J M Entrena; F R Nieto; C M Cendán; E Del Pozo
Journal:  Curr Neuropharmacol       Date:  2008-12       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.